Currently, cisplatin is the first-line chemotherapy drug for a variety of malignant tumours and HIF-1α is associated with cisplatin-resistance (124).However, in the cisplatin-sensitive ovarian cancer cells, cisplatin promotes HIF-1α degradation via the proteasome pathway, induces the downregulation of LDH-A expression, and then increases the level of reactive oxygen species (ROS) by inducing the cells to produce ATP through oxidative phosphorylation, which modulates cisplatin resistance and promotes the death of ovarian cancer cells (125–127) (Figure 4). Here, HIF1A is linked to ovarian cancer.